Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Relapse/Refractory Multiple Myeloma Clinical Trial

Official title:

Efficacy and Safety of Paclitaxel/Cyclophosphamide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaRefractory

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02985333
• Other study ID #: MM-2014
• Status: Withdrawn
• Phase: Phase 2
• Start date: January 2014
• Est. completion date: June 2019

Study information

• Verified date: December 2016
• Source: Sun Yat-sen University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of paclitaxel in combination with cyclophosphamide and dexamethasone in chinese patients with relapsed/refractory multiple myeloma.

Description:

Treatment for relapsed/refractory multiple myeloma (MM)remains a crucial challenge.The investigators have previously shown that the combination of paclitaxel and cyclophosphamide acts synergistically to induce apoptosis of myeloma cells in vitro. Based on these preclinical studies, the investigators initiated a phase II clinical trial of paclitaxel 175 mg/m(2) IV over 3 h d1 combined with cyclophosphamide 200 mg/m(2) IV over 30-60 min d1,3,5 and dexamethasone 20mg IV over 30-60 min d1-4 in patients with relapsed or refractory MM. This regimen was administered every four weeks for a total of six cycles

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: June 2019
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patient has a previous diagnosis of multiple myeloma

• Patient requires retreatment for multiple myeloma

• Subject has measurable disease as defined by > 0.5 g/dL serum monoclonal protein, >10 mg/dL involved serum free light chain (either kappa or lambda) provided that the serum free light chain ratio is abnormal, >0.2 g/24 hrs urinary M-protein excretion, and/or measurable plasmacytoma(s) of at least 1cm in greatest dimension as measured by either CT scanning or MRI

• Subject has a Karnofsky performance status =60% (>50% if due to bony involvement of myeloma (see Appendix IV)

• Subject has a life expectancy = 3 months

• Subjects must meet the following laboratory parameters:

Absolute neutrophil count (ANC) =750 cells/mm3 (1.0 x 109/L) Hemoglobin = 7 g/dL Platelet count = 75,000/mm3 (30 x 109/L if extensive bone marrow infiltration) Serum SGOT/AST <3.0 x upper limits of normal (ULN) Serum SGPT/ALT <3.0 x upper limits of normal (ULN) Serum total bilirubin <2.0 mg/dL (34 µmol/L) Creatinine clearance = 45 cc/min

Exclusion Criteria:

• Subject has immeasurable MM (no measurable monoclonal protein, free light chains in blood or urine, or measureable plasmacytoma on radiologic scanning)

• Subject has a prior history of other malignancies unless disease-free for = 5 years, except for basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or localized prostate cancer with Gleason score < 7 with stable prostate specific antigen (PSA) levels

• Subject has had myocardial infarction within 6 months prior to enrollment, or NYHA (New York Hospital Association) Class III or IV heart failure (see Appendix VI), Ejection Fraction < 35%, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities

• Female subject who is pregnant or lactating

• Subject has known HIV infection

• Subject has known active hepatitis B or hepatitis C infection

• Subject has active viral or bacterial infections or any coexisting medical problem that would significantly increase the risks of this treatment program

• Subject is unable to reliably take oral medications

• Subject has known hypersensitivity to dexamethasone,cyclophosphamide,paclitaxel

• Subject has a history of thromboembolic event within the past 4 weeks prior to enrollment

• Subject has any clinically significant medical or psychiatric disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a subject's ability to give informed consent

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapse/Refractory Multiple Myeloma

Intervention

Drug:
• Paclitaxel
Paclitaxel 170 mg/m(2) IV over 3 h d1
• Cyclophosphamide
Cyclophosphamide 200mgmg/m(2) IV d1,3,5
• Dexamethasone
Dexamethasone 20mg iv d1-4

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	ORR is defined as the proportion of patients with CR, nCR or partial response (PR) based on modified EBMT criteria per investigator assessment	30 months
Secondary	Progression Free Survival (PFS)	PFS, defined as time from first dose of study treatment to progression or death due to any cause, as assessed by investigator	30 months
Secondary	Overall survival (OS)	OS, defined as time from first dose of study treatment to death	30 months
Secondary	Safety of combination therapy assessed using the National Cancer institute-Common Toxicology Criteria (NCI-CTC) grade scale for AEs and Lab assessments	Safety of combination therapy as assessed by toxicity, which will be assessed using the National Cancer Institute-Common Toxicology Criteria (NCI-CTC) grading scale for Adverse Events and for laboratory assessments (v4.03) that include biochemistry, hematology, urinalysis; special safety assessments that include LVEF, Thyroid function Creatinine clearance and ECGs (electrocardiograms).	30 months